Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective.

Ho CM, Chen HL, Hu RH, Lee PH.

Ther Adv Med Oncol. 2019 Apr 26;11:1758835919843463. doi: 10.1177/1758835919843463. eCollection 2019. Review.

2.

Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment.

Siu EH, Chan AW, Chong CC, Chan SL, Lo KW, Cheung ST.

Transl Gastroenterol Hepatol. 2018 Nov 7;3:89. doi: 10.21037/tgh.2018.10.16. eCollection 2018. Review.

3.

Use of checkpoint inhibitors in liver transplant recipients.

Munker S, De Toni EN.

United European Gastroenterol J. 2018 Aug;6(7):970-973. doi: 10.1177/2050640618774631. Epub 2018 Apr 30. Review.

4.

CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.

Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG.

Hepatology. 2015 May;61(5):1591-602. doi: 10.1002/hep.27665. Epub 2015 Mar 20.

5.

Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.

Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, Mancham S, Pedroza-Gonzalez A, Polak WG, de Jonge J, Gaspersz M, Dong H, Thielemans K, Pan Q, IJzermans JNM, Bruno MJ, Kwekkeboom J.

Gastroenterology. 2017 Oct;153(4):1107-1119.e10. doi: 10.1053/j.gastro.2017.06.017. Epub 2017 Jun 23.

PMID:
28648905
6.

Immune Checkpoint Inhibitors in Organ Transplant Patients.

Kittai AS, Oldham H, Cetnar J, Taylor M.

J Immunother. 2017 Sep;40(7):277-281. doi: 10.1097/CJI.0000000000000180. Review.

PMID:
28719552
7.

Immune checkpoint therapy in liver cancer.

Xu F, Jin T, Zhu Y, Dai C.

J Exp Clin Cancer Res. 2018 May 29;37(1):110. doi: 10.1186/s13046-018-0777-4. Review.

8.

Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.

Shrestha R, Prithviraj P, Anaka M, Bridle KR, Crawford DHG, Dhungel B, Steel JC, Jayachandran A.

Front Oncol. 2018 Jul 13;8:269. doi: 10.3389/fonc.2018.00269. eCollection 2018.

9.

IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.

Liu H, Shen J, Lu K.

Biochem Biophys Res Commun. 2017 Apr 29;486(2):239-244. doi: 10.1016/j.bbrc.2017.02.128. Epub 2017 Mar 1.

PMID:
28254435
10.

Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience.

DeLeon TT, Salomao MA, Aqel BA, Sonbol MB, Yokoda RT, Ali AH, Moss AA, Mathur AK, Chascsa DM, Rakela J, Bryce AH, Borad MJ.

J Gastrointest Oncol. 2018 Dec;9(6):1054-1062. doi: 10.21037/jgo.2018.07.05.

11.

Program death-1 immune checkpoint and tumor microenvironment in malignant liver tumors.

Moris D, Rahnemai-Azar AA, Zhang X, Ntanasis-Stathopoulos I, Tsilimigras DI, Chakedis J, Argyrou C, Fung JJ, Pawlik TM.

Surg Oncol. 2017 Dec;26(4):423-430. doi: 10.1016/j.suronc.2017.08.005. Epub 2017 Sep 1. Review.

PMID:
29113661
12.

Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients.

Chae YK, Galvez C, Anker JF, Iams WT, Bhave M.

Cancer Treat Rev. 2018 Feb;63:116-121. doi: 10.1016/j.ctrv.2017.12.004. Epub 2017 Dec 8. Review.

PMID:
29276997
13.

Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report.

Owonikoko TK, Kumar M, Yang S, Kamphorst AO, Pillai RN, Akondy R, Nautiyal V, Chatwal MS, Book WM, Sahu A, Sica GL, Ahmed R, Ramalingam SS.

Cancer Immunol Immunother. 2017 Jan;66(1):45-50. doi: 10.1007/s00262-016-1918-2. Epub 2016 Oct 22.

14.

An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma.

Cheng JW, Shi YH, Fan J, Huang XW, Qiu SJ, Xiao YS, Wang Z, Dai Z, Tang ZY, Zhou J.

J Cancer Res Clin Oncol. 2011 Oct;137(10):1445-53. doi: 10.1007/s00432-011-1014-0. Epub 2011 Aug 2.

PMID:
21809031
15.

Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction.

Shi XL, Mancham S, Hansen BE, de Knegt RJ, de Jonge J, van der Laan LJ, Rivadeneira F, Metselaar HJ, Kwekkeboom J.

J Hepatol. 2016 Jun;64(6):1274-82. doi: 10.1016/j.jhep.2016.02.034. Epub 2016 Mar 3.

PMID:
26941095
16.

Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives.

Roth GS, Decaens T.

Eur J Cancer. 2017 Dec;87:101-112. doi: 10.1016/j.ejca.2017.10.010. Epub 2017 Nov 13. Review.

PMID:
29145036
17.

Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.

Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, Hsu JL, Li CW, Lim SO, Sheng YY, Zhang Y, Li JH, Luo Q, Zheng Y, Zhao Y, Lu L, Jia HL, Hung MC, Dong QZ, Qin LX.

Gut. 2019 Mar 22. pii: gutjnl-2019-318419. doi: 10.1136/gutjnl-2019-318419. [Epub ahead of print]

PMID:
30902885
18.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

19.

Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.

Zhou J, Liu M, Sun H, Feng Y, Xu L, Chan AWH, Tong JH, Wong J, Chong CCN, Lai PBS, Wang HK, Tsang SW, Goodwin T, Liu R, Huang L, Chen Z, Sung JJ, Chow KL, To KF, Cheng AS.

Gut. 2018 May;67(5):931-944. doi: 10.1136/gutjnl-2017-314032. Epub 2017 Sep 22.

20.

Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model.

Llopiz D, Ruiz M, Villanueva L, Iglesias T, Silva L, Egea J, Lasarte JJ, Pivette P, Trochon-Joseph V, Vasseur B, Dixon G, Sangro B, Sarobe P.

Cancer Immunol Immunother. 2019 Mar;68(3):379-393. doi: 10.1007/s00262-018-2283-0. Epub 2018 Dec 13.

PMID:
30547218

Supplemental Content

Support Center